Loading organizations...
§ Venture Capital · Singapore, Central Region, Singapore
Infinitum Asset Management operates as a hedge fund, focusing on global opportunistic equity long/short strategies. It aims for asymmetric returns by identifying undervalued smaller companies and exploring less-trafficked investment ideas, complemented by strategic short selling. The firm's approach emphasizes rigorous research to uncover mispriced assets across various market conditions.
The firm was established in the third quarter of 2018 by its founder, John Yetimoglu, who also serves as its Chief Investment Officer. Yetimoglu embarked on this venture, drawing inspiration from the investment philosophy of Julian Robertson. This foundational insight drives the firm’s commitment to skilled, active management in generating returns.
Infinitum Asset Management serves sophisticated investors seeking actively managed strategies to capitalize on market inefficiencies. The firm's long-term vision centers on delivering superior risk-adjusted returns through disciplined research and a flexible investment mandate, continuously adapting to market dynamics to pursue growth opportunities.
Infinitum Asset Management has 1 tracked investment across 1 company. The latest tracked deal is $155.0M Series B in ArriVent Biopharma in March 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 27, 2023 | ArriVent Biopharma | $155.0M Series B | Elena Viboch, James Healy | Aihc Capital, Catalio Capital, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Lilly Asia Ventures, Octagon Capital, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital, Terra Magnum Capital Partners, Unicorn Capital, ZOO Capital |